

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM592782

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST FOR TRADEMARK SECURITY AGREEMENT FILED AT REEL/FRAE 6638/0116		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
BPCR LIMITED PARTNERSHIP		08/18/2020	Limited Partnership: ENGLAND
RECEIVING PARTY DATA			
Name:	NOVOCURE GMBH		
Street Address:	PARK 6		
City:	ROOT D4		
State/Country:	SWITZERLAND		
Entity Type:	Corporation: SWITZERLAND		
PROPERTY NUMBERS Total: 4			
Property Type	Number	Word Mark	
Registration Number:	4899330	OPTUNE	
Registration Number:	5616214	NOVOCURE	
Serial Number:	88385697	NOVOCURE	
Serial Number:	88169359	NCOMPASS	
CORRESPONDENCE DATA			
Fax Number:	2149813400		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	2149813300		
Email:	lggrau@sidley.com		
Correspondent Name:	Lauren G. Grau		
Address Line 1:	2021 McKinney Ave		
Address Line 2:	Suite 2000, c/o Sidley Austin		
Address Line 4:	Dallas, TEXAS 75201		
ATTORNEY DOCKET NUMBER:	55118-10220		
NAME OF SUBMITTER:	Lauren G. Grau		
SIGNATURE:	/Lauren G. Grau/		
DATE SIGNED:	08/19/2020		
Total Attachments: 5			

CH \$115.00 4899330

source=BPCR-NovoCure - Release of Trademark Security Interest (2020)#page1.tif
source=BPCR-NovoCure - Release of Trademark Security Interest (2020)#page2.tif
source=BPCR-NovoCure - Release of Trademark Security Interest (2020)#page3.tif
source=BPCR-NovoCure - Release of Trademark Security Interest (2020)#page4.tif
source=BPCR-NovoCure - Release of Trademark Security Interest (2020)#page5.tif

RELEASE OF TRADEMARK SECURITY INTEREST

THIS RELEASE OF TRADEMARK SECURITY INTEREST (this “Release”) is made as of August 18 2020, (“Effective Date”) by BPCR LIMITED PARTNERSHIP in its capacity as lender (in such capacity, the “Lender”), in favor of NOVOCURE GMBH (the “Grantor”). All terms not herein defined, have the meanings set forth in the Loan Agreement, the Security Agreement and the TM Agreement referenced below.

WHEREAS, NovoCure Limited and the Lender (as successor-in-interest to BioPharma Credit PLC (“BioPharma”)) entered into that certain Loan and Security Agreement dated as of February 7, 2018 (as amended, restated, supplemented or otherwise modified from time to time, the “Loan Agreement”);

WHEREAS, in connection with the Loan Agreement, the Grantor and the Lender (as successor-in-interest to BioPharma) entered into that certain Guaranty and Security Agreement dated as of February 7, 2018 (as amended, restated, supplemented or otherwise modified from time to time, the “Security Agreement”) executed in order to secure the prompt and complete payment, observance and performance of all of the Obligations in accordance with the terms and conditions of the Loan Agreement and the various other loan documents;

WHEREAS, pursuant to the Security Agreement, the Grantor was required to execute and deliver a Trademark Security Agreement dated as of April 24, 2019 (the “TM Agreement”) to the Lender (as successor-in-interest to BioPharma) for purposes of filing with the United States Patent and Trademark Office (“USPTO”);

WHEREAS, pursuant to the Security Agreement and the TM Agreement, the Grantor granted to the Lender, on behalf of itself and the other Secured Parties, among other Trademark Collateral as set forth therein, a continuing security interest in and continuing lien upon all of the Grantor’s right, title and interest, including goodwill in the trademarks, in, to and under the United States trademarks registrations and applications listed on the attached Schedule A (the “Trademarks”);

WHEREAS, the TM Agreement was recorded in the USPTO on May 6, 2019 at Reel/Frame 6638/0116; and

WHEREAS, the Lender, on behalf of itself and the other Secured Parties, wishes to release its continuing security interest in and continuing liens upon the Trademark Collateral, including the Trademarks on Schedule A, in accordance with the Security Agreement.

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Lender, on behalf of itself and the other Secured Parties, hereby (i) terminates, releases and fully discharges its continuing security interest in and continuing lien upon the Trademark Collateral, including the Trademarks on Schedule A, (ii) waives and relinquishes all of its rights, powers, privileges and remedies with respect to the Trademark Collateral, and (iii) assigns, transfers, and conveys to the Grantor any and all right, title or interest in, or to, the Trademark Collateral that the Lender may hold.

This Release has been executed and delivered by the Lender for the purpose of recording with the USPTO (and the Lender hereby authorizes such recording).

The Lender agrees, at the Grantor's expense, to take all further actions, and provide to the Grantor and its successors, assigns and legal representatives all such cooperation and assistance, including, without limitation, the execution and delivery of any and all further documents or other instruments, as the Grantor and its successors, assigns and legal representatives may reasonably request in order to confirm, effectuate or record this Release.

This Release shall be governed by, and construed and interpreted in accordance with, the law of the State of New York.

[Signature Page Follows]

IN WITNESS WHEREOF, the Lender has caused this Release to be executed by its duly authorized representative effective as of the Effective Date.

BPCR LIMITED PARTNERSHIP, as Lender

By: Pharmakon Advisors, LP,
its Investment Manager

By: Pharmakon Management I, LLC,
its General Partner

By: 
Name: Pedro Gonzalez de Cosio
Title: Managing Member


Signature Page to Release of Trademark Security Interest

TRADEMARK
REEL: 007028 FRAME: 0306

SCHEDULE A

Trademarks

1. REGISTERED TRADEMARKS

<u>Name of Entity</u>	<u>Country</u>	<u>Mark</u>	<u>Status</u>	<u>Serial No. / Date Registration No.</u>
NovoCure Limited	European Union		Published	SN: 17963450 Filed: 10/1/2018
NovoCure Limited	European Union	NOVOCURE	Registered	SN: 17498833 Filed: 11/20/2017 RN: 17498833
NovoCure Limited	Japan	NOVOCURE	Registered	SN: 2017-157220 Filed: 11/29/2017
NovoCure Limited	United States	NOVOCURE	Registered	SN: 87864623 Filed: 4/5/2018 RN: 5616214
NovoCure Limited	China	NOVOCURE OPTUNE	Published	SN: 32940390 Filed 8/16/2018
NovoCure Limited	China	NOVOCURE	Published	SN: 32932060 Filed: 8/16/2018
NovoCure Limited	European Union	OPTUNE	Registered	SN: 13436911 Filed: 11/6/2014 RN: 13436911
NovoCure Limited	Israel	OPTUNE	Registered	SN: 269517 Filed: 11/9/2014 RN: 269517
NovoCure Limited	Japan	OPTUNE	Registered	SN: 2014-093406 Filed: 11/6/2014 RN: 5805705
NovoCure Limited	Switzerland	OPTUNE	Registered	SN: 669056/2014 Filed: 11/6/2014 RN: 669056
NovoCure Limited	United States	OPTUNE	Registered	SN: 86437407 Filed: 10/28/2014 RN: 4899330
NovoCure Limited	China	OPTUNE BY NOVOCURE	Published	SN: 32932087 Filed: 8/16/2018
NovoCure Limited	Japan	OPTUNE in Japanese Characters	Registered	SN: 2015-078221 Filed: 8/14/2015 RN: 5817879
NovoCure Limited	Macau	OPTUNE	Published	SN N/149630 Filed 1/22/2019

2. TRADEMARKS APPLICATIONS

<u>Name of Entity</u>	<u>Country</u>	<u>Mark</u>	<u>Status</u>	<u>Serial No. / Date Registration No.</u>
NovoCure Limited	United States	novocure	Pending	SN: 88385697 Filed 4/15/2019
NovoCure Limited	Switzerland	n-COMPASS	Pending	SN: 80068/2018 Filed: 10/18/2018
NovoCure Limited	United States	n-COMPASS	Pending	SN: 88169359 Filed: 10/25/2018
NovoCure Limited	China	NCOMPASS	Pending	SN: 33961342 Filed: 10/11/2018
NovoCure Limited	Japan	NCOMPASS	Pending	SN: 2018-123564 Filed: 10/1/2018
NovoCure Limited	Canada	NOVOCURE	Pending	SN: 1903446 Filed: 6/8/2018
NovoCure Limited	China	NOVOCURE	Pending	SN: 32940377 Filed 8/16/2018
NovoCure Limited	Israel	NOVOCURE	Pending	SN: 300343 Filed: 11/22/2017
NovoCure Limited	Switzerland	NOVOCURE	Pending	SN: 50320/2018 Filed: 1/10/2018
NovoCure Limited	China	OPTUNE	Pending	SN: 32923056 Filed 8/16/2018
NovoCure Limited	Taiwan	OPTUNE	Pending	SN 107084459 Filed 12/28/2018
NovoCure Limited	China	OPTUNE 150 kHz	Pending	SN: 32927353 Filed 8/16/2018
NovoCure Limited	China	OPTUNE 200 kHz	Pending	SN: 32928842 Filed 8/16/2018